Free Trial
NASDAQ:CDIO

Cardio Diagnostics 5/15/2025 Earnings Report

Cardio Diagnostics logo
$1.83 -0.14 (-7.11%)
Closing price 04:00 PM Eastern
Extended Trading
$1.90 +0.06 (+3.55%)
As of 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardio Diagnostics EPS Results

Actual EPS
-$0.97
Consensus EPS
-$0.06
Beat/Miss
Missed by -$0.91
One Year Ago EPS
N/A

Cardio Diagnostics Revenue Results

Actual Revenue
$0.00 million
Expected Revenue
$0.05 million
Beat/Miss
Missed by -$49.00 thousand
YoY Revenue Growth
N/A

Cardio Diagnostics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Cardio Diagnostics' next earnings date is estimated for Thursday, May 14, 2026, based on past reporting schedules.

Conference Call Resources

Cardio Diagnostics Earnings Headlines

Elon Musk’s $1 Quadrillion AI IPO
$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.tc pixel
Why Cardio Diagnostics Holdings (CDIO) is 'One to Watch'
IBN Initiates Coverage of Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings (CDIO) Is 'One to Watch'
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

View Cardio Diagnostics Profile